Trevi Therapeutics (TRVI) Non-Current Assets (2018 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Non-Current Assets of $3.5 million for Q1 2026, up 151.99% year-over-year from $1.4 million in Q1 2025, and up 95.46% quarter-over-quarter from $1.8 million in Q4 2025.
Trevi Therapeutics (TRVI) Non-Current Assets (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Non-Current Assets history runs 9 years deep, the most recent figure standing at $3.5 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 151.99% year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at $7.4 million (up 21.74% YoY), while the FY2025 annual figure was $1.8 million, up 21.13% from the prior year.
- Non-Current Assets for Q1 2026 stood at $3.5 million, up from $1.8 million in the prior quarter.
- The five-year high for Non-Current Assets was $3.5 million in Q1 2026, with the low at $399000.0 in Q4 2022.
- The 5-year median for Non-Current Assets is $1.6 million (2024), against an average of $1.6 million.
- The sharpest annual moves came in 2023 and 2025: Non-Current Assets soared 365.16% in 2023, then tumbled 33.91% in 2025.
- Trevi Therapeutics' Non-Current Assets stood at $399000.0 in 2022, then jumped by 365.16% to $1.9 million in 2023, then declined by 20.69% to $1.5 million in 2024, then climbed by 21.13% to $1.8 million in 2025, then surged by 95.46% to $3.5 million in 2026.
- Business Quant data shows TRVI's Non-Current Assets at $3.5 million in Q1 2026, $1.8 million in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - | 4.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.81 Mn |
| Mar 31, 2026 | 3.49 Mn |
| Dec 31, 2025 | 1.78 Mn |
| Sep 30, 2025 | 1.06 Mn |
| Jun 30, 2025 | 1.11 Mn |
| Mar 31, 2025 | 1.38 Mn |
| Dec 31, 2024 | 1.47 Mn |
| Sep 30, 2024 | 1.57 Mn |
| Jun 30, 2024 | 1.68 Mn |
| Mar 31, 2024 | 1.79 Mn |
| Dec 31, 2023 | 1.86 Mn |
| Sep 30, 2023 | 1.94 Mn |
| Jun 30, 2023 | 1.76 Mn |
| Mar 31, 2023 | 2.00 Mn |
| Dec 31, 2022 | 399,000.00 |
| Sep 30, 2022 | 1.04 Mn |
| Jun 30, 2022 | 1.53 Mn |
| Mar 31, 2022 | 547,000.00 |
| Dec 31, 2021 | 518,000.00 |
| Sep 30, 2021 | 889,000.00 |